iShares Trust. Holdings as of Jun 30, 2026, from Form N-PORT.
Share of net assets at the report date, for the whole fund across all share classes.
| Holding | Weight | Value | Shares or units |
|---|---|---|---|
| BlackRock Funds IIICash or money market | 11.66% | $1.06B | 1,059,406,269 |
| Vertex Pharmaceuticals, Inc.VRTX | 8.08% | $734.32M | 1,478,300 |
| Amgen, Inc.AMGN | 7.83% | $711.36M | 1,964,435 |
| Gilead Sciences, Inc.GILD | 6.84% | $621.79M | 4,921,526 |
| Regeneron Pharmaceuticals, Inc.REGN | 4.91% | $445.87M | 715,060 |
| Argenx SEARGX | 3.76% | $341.58M | 368,177 |
| Alnylam Pharmaceuticals, Inc.ALNY | 3.12% | $283.62M | 942,174 |
| Natera, Inc.NTRA | 2.89% | $262.68M | 967,683 |
| Revolution Medicines, Inc.RVMD | 2.78% | $252.66M | 1,349,118 |
| Biogen, Inc.BIIB | 2.47% | $224.09M | 1,037,164 |
| Illumina, Inc.ILMN | 2.07% | $188.03M | 1,069,358 |
| Moderna, Inc.MRNA | 1.98% | $180.31M | 2,574,707 |
| Insmed, Inc.INSM | 1.78% | $162.20M | 1,521,319 |
| BeOne Medicines Ltd.ONC | 1.77% | $160.77M | 564,180 |
| Incyte Corp.INCY | 1.75% | $159.00M | 1,402,629 |
| United Therapeutics Corp.UTHR | 1.73% | $157.56M | 290,800 |
| Roivant Sciences Ltd. | 1.43% | $129.59M | 3,661,689 |
| Neurocrine Biosciences, Inc.NBIX | 1.30% | $117.98M | 700,051 |
| Ascendis Pharma A/S | 1.29% | $116.86M | 438,135 |
| Genmab A/SGMAB | 1.12% | $101.67M | 3,701,095 |
| Exelixis, Inc.EXEL | 1.03% | $93.91M | 1,726,035 |
| Ionis Pharmaceuticals, Inc.IONS | 1.00% | $91.06M | 1,148,496 |
| Bridgebio Pharma, Inc.BBIO | 0.98% | $89.23M | 1,198,062 |
| Medpace Holdings, Inc.MEDP | 0.95% | $86.35M | 163,042 |
| Madrigal Pharmaceuticals, Inc.MDGL | 0.91% | $82.55M | 153,736 |
| Bio-Techne Corp.TECH | 0.86% | $78.10M | 1,105,421 |
| BioMarin Pharmaceutical, Inc.BMRN | 0.85% | $77.17M | 1,348,623 |
| Charles River Laboratories International, Inc.CRL | 0.84% | $76.49M | 337,267 |
| Arrowhead Pharmaceuticals, Inc.ARWR | 0.84% | $76.43M | 937,699 |
| Axsome Therapeutics, Inc.AXSM | 0.82% | $74.69M | 305,148 |
| Cytokinetics, Inc.CYTK | 0.79% | $71.93M | 844,381 |
| Krystal Biotech, Inc.KRYS | 0.75% | $67.75M | 182,295 |
| Halozyme Therapeutics, Inc.HALO | 0.72% | $65.11M | 831,875 |
| Praxis Precision Medicines, Inc.PRAX | 0.68% | $61.94M | 185,012 |
| Abivax SAABVX | 0.67% | $61.14M | 458,824 |
| Alkermes plc | 0.67% | $60.51M | 1,154,946 |
| BioNTech SEBNTX | 0.66% | $60.22M | 647,133 |
| Vaxcyte, Inc.PCVX | 0.64% | $58.16M | 1,000,469 |
| Kymera Therapeutics, Inc.KYMR | 0.64% | $57.80M | 504,074 |
| Apogee Therapeutics, Inc. | 0.59% | $53.58M | 403,675 |
| Protagonist Therapeutics, Inc.PTGX | 0.58% | $53.00M | 432,356 |
| Rhythm Pharmaceuticals, Inc.RYTM | 0.57% | $52.22M | 470,310 |
| Repligen Corp.RGEN | 0.57% | $51.60M | 378,157 |
| Spyre Therapeutics, Inc.SYRE | 0.54% | $48.62M | 547,684 |
| Bruker Corp.BRKR | 0.52% | $47.39M | 787,539 |
| PTC Therapeutics, Inc.PTCT | 0.51% | $46.32M | 567,871 |
| Nuvalent, Inc. | 0.50% | $45.70M | 370,035 |
| Twist Bioscience Corp.TWST | 0.48% | $43.45M | 422,334 |
| Tempus AI, Inc.TEM | 0.48% | $43.37M | 748,648 |
| Mirum Pharmaceuticals, Inc.MIRM | 0.45% | $41.14M | 351,444 |
Holdings from the fund's latest Form N-PORT; expense ratio (net of fee waivers) from the risk/return summary of its prospectus; fund type from Form N-CEN. Prices are end-of-day closes adjusted for splits; total return also reinvests distributions.